CCL Products
CCL Products
Consumer GoodsKey Fundamentals
MicrocapTea & CoffeeConsumer GoodsTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company has reduced debt.
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 21.8%
Weaknesses
1- Stock is trading at 6.16 times its book value
Growth Rate
AI Analysis — Bull vs Bear
CCL Products (India) Ltd, the world's largest private-label instant coffee manufacturer, trades at a market cap of ₹14,258 Cr with a P/E of 33.8x and P/B of 6.24x. The company has delivered strong TTM sales growth of 36% and profit growth of 39%, while maintaining a consistent ROE of 17-18% over the past decade, though its valuation multiples remain elevated relative to book value.
- TTM sales growth of 36% significantly outpaces the 10-year compounded sales CAGR of 17%, indicating accelerating revenue momentum
- TTM profit growth of 39% exceeds TTM sales growth of 36%, suggesting improving operating leverage and margin expansion
- Consistent ROE maintained at 17-18% across 3-year, 5-year, and 10-year periods, demonstrating durable return on equity
- Company has been actively reducing debt, strengthening its balance sheet and lowering financial risk
- 5-year compounded sales CAGR of 29% reflects sustained top-line growth well above nominal GDP growth rates
- Healthy dividend payout ratio of 21.8% with a dividend yield of 0.52%, indicating shareholder return discipline while retaining capital for growth
- Stock price CAGR of 22% over 5 years reflects strong long-term wealth creation, broadly in line with underlying earnings compounding
- 5-year compounded profit CAGR of 16% demonstrates consistent double-digit earnings growth over a meaningful period
- P/B ratio of 6.24x is elevated, meaning the stock trades at more than six times its book value, leaving limited margin of safety
- P/E of 33.8x is a premium valuation that already prices in significant future growth, increasing downside risk if growth disappoints
- 3-year compounded profit CAGR of only 11% is materially lower than the 3-year sales CAGR of 29%, suggesting periods of margin compression
- 10-year compounded profit CAGR of 12% trails the 10-year sales CAGR of 17%, indicating long-term profit growth has not kept pace with revenue growth
- Dividend yield of just 0.52% offers minimal income return relative to risk-free alternatives yielding over 7%
- As a commodity-linked business, CCL is exposed to global coffee bean price volatility, which can compress margins in rising input cost environments
- 1-year stock price CAGR of 22% has run ahead of the 10-year profit CAGR of 12%, suggesting valuation re-rating rather than pure earnings-driven appreciation
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Strong FY26 revenue and profit Aug 17
Consolidated revenue rose 43.5% YoY to ₹4,457.37 crore in FY26, with PAT up 25.1% to ₹388.11 crore and ROCE improving to 22.15% from 18.21%.
- 80% renewable energy achieved Aug 17
BRSR filing shows 80% renewable energy consumption in FY26, 971 tCO2e avoided via solar, and 90% responsible sourcing of inputs.
- ₹3 dividend approved at AGM Sep 8
Shareholders approved a ₹3.00 per share final dividend for FY26 and re-elected two retiring directors at the 65th AGM with near-universal voting participation.
TL;DR: CCL Products delivered a strong FY26 with 43.5% revenue growth and meaningful margin expansion, supported by robust volume or pricing gains in its coffee business. ESG credentials are strengthening with 80% renewable energy and responsible sourcing. No material headwinds surfaced in recent news flow. The trend is clearly improving, though investors should watch whether this revenue growth pace is sustainable into FY27 given a high base.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 655 | 608 | 664 | 727 | 773 | 738 | 758 | 836 | 1,056 | 1,127 | 1,051 | 1,224 | 1,200 |
| Expenses | 549 | 498 | 554 | 609 | 643 | 601 | 634 | 673 | 897 | 930 | 866 | 1,033 | 1,007 |
| Operating Profit | 106 | 110 | 111 | 118 | 130 | 137 | 124 | 163 | 159 | 197 | 185 | 192 | 194 |
| OPM % | 16% | 18% | 17% | 16% | 17% | 19% | 16% | 20% | 15% | 18% | 18% | 16% | 16% |
| Other Income | 0 | 1 | 1 | 4 | 1 | 1 | 3 | 4 | 2 | 1 | 3 | 2 | 3 |
| Interest | 15 | 18 | 23 | 21 | 21 | 27 | 31 | 34 | 34 | 33 | 32 | 30 | 29 |
| Depreciation | 22 | 23 | 22 | 31 | 23 | 24 | 25 | 27 | 34 | 39 | 39 | 40 | 39 |
| PBT | 69 | 70 | 67 | 70 | 87 | 87 | 72 | 106 | 94 | 127 | 116 | 123 | 129 |
| Tax % | 13% | 13% | 5% | 7% | 18% | 15% | 12% | 4% | 23% | 21% | 14% | 7% | 9% |
| Net Profit | 61 | 61 | 63 | 65 | 71 | 74 | 63 | 102 | 72 | 101 | 100 | 115 | 117 |
| EPS in Rs | 4.56 | 4.57 | 4.76 | 4.88 | 5.35 | 5.54 | 4.72 | 7.63 | 5.43 | 7.55 | 7.51 | 8.58 | 8.75 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 881 | 932 | 976 | 1,138 | 1,081 | 1,139 | 1,242 | 1,462 | 2,071 | 2,654 | 3,106 | 4,457 | 4,602 |
| Expenses | 709 | 727 | 744 | 899 | 836 | 853 | 945 | 1,131 | 1,671 | 2,208 | 2,551 | 3,723 | 3,835 |
| Operating Profit | 171 | 205 | 232 | 239 | 245 | 286 | 298 | 331 | 400 | 445 | 555 | 734 | 767 |
| OPM % | 19% | 22% | 24% | 21% | 23% | 25% | 24% | 23% | 19% | 17% | 18% | 16% | 17% |
| Other Income | 3 | 1 | 1 | 5 | 3 | 4 | 3 | 4 | 3 | 6 | 8 | 7 | 9 |
| Interest | 14 | 11 | 11 | 8 | 8 | 18 | 17 | 16 | 34 | 78 | 113 | 129 | 124 |
| Depreciation | 27 | 28 | 33 | 34 | 32 | 47 | 49 | 57 | 64 | 98 | 98 | 152 | 157 |
| PBT | 134 | 167 | 189 | 202 | 209 | 225 | 235 | 261 | 305 | 276 | 352 | 461 | 496 |
| Tax % | 30% | 27% | 29% | 27% | 26% | 26% | 22% | 22% | 7% | 9% | 12% | 16% | — |
| Net Profit | 94 | 122 | 135 | 148 | 155 | 166 | 182 | 204 | 284 | 250 | 310 | 388 | 433 |
| EPS in Rs | 7.06 | 9.18 | 10.12 | 11.14 | 11.64 | 12.47 | 13.7 | 15.36 | 21.35 | 18.73 | 23.24 | 29.07 | 32.39 |
| Div. Payout % | 21% | 27% | 25% | 22% | 30% | 40% | 29% | 33% | 26% | 24% | 22% | 20% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 |
| Reserves | 395 | 483 | 602 | 713 | 812 | 902 | 1,061 | 1,224 | 1,471 | 1,647 | 1,941 | 2,318 |
| Borrowings | 229 | 210 | 142 | 311 | 416 | 469 | 559 | 655 | 920 | 1,622 | 1,815 | 1,324 |
| Other Liabilities | 111 | 81 | 78 | 83 | 166 | 112 | 142 | 164 | 180 | 240 | 459 | 657 |
| Total Liabilities | 762 | 801 | 848 | 1,134 | 1,422 | 1,509 | 1,788 | 2,070 | 2,597 | 3,536 | 4,241 | 4,326 |
| Fixed Assets | 340 | 417 | 393 | 371 | 383 | 724 | 798 | 882 | 1,257 | 1,252 | 1,622 | 2,027 |
| CWIP | 53 | 0 | 0 | 226 | 424 | 100 | 149 | 160 | 54 | 501 | 450 | 3 |
| Investments | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
| Other Assets | 367 | 382 | 453 | 535 | 613 | 684 | 841 | 1,028 | 1,286 | 1,783 | 2,169 | 2,293 |
| Total Assets | 762 | 801 | 848 | 1,134 | 1,422 | 1,509 | 1,788 | 2,070 | 2,597 | 3,536 | 4,241 | 4,326 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 105 | 161 | 102 | 145 | 162 | 91 | 171 | 116 | 173 | 55 | 290 | 858 |
| Investing | -19 | -87 | -20 | -247 | -175 | -88 | -153 | -192 | -307 | -527 | -415 | 18 |
| Financing | -93 | -82 | -84 | 129 | 42 | -37 | 64 | 9 | 164 | 559 | 53 | -757 |
| Net Cash Flow | -8 | -8 | -2 | 27 | 29 | -35 | 82 | -67 | 30 | 86 | -72 | 120 |
| Free Cash Flow | 84 | 74 | 84 | -78 | -80 | 2 | 16 | -74 | -159 | -458 | -128 | 788 |
| CFO/OP | 86 | 97 | 67 | 84 | 89 | 50 | 66 | 47 | 52 | 19 | 57 | 123 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 47 | 50 | 61 | 58 | 79 | 86 | 88 | 80 | 78 | 68 | 81 | 67 |
| Inventory Days | 116 | 99 | 121 | 97 | 123 | 170 | 198 | 262 | 187 | 185 | 208 | 131 |
| Days Payable | 29 | 8 | 8 | 5 | 35 | 16 | 13 | 23 | 24 | 23 | 44 | 32 |
| Cash Conversion Cycle | 134 | 142 | 174 | 150 | 168 | 240 | 272 | 319 | 241 | 230 | 246 | 166 |
| Working Capital Days | 45 | 37 | 81 | 89 | 43 | 103 | 59 | 77 | 58 | 40 | 42 | 41 |
| ROCE % | 23% | 26% | 27% | 23% | 19% | 18% | 17% | 16% | 16% | 12% | 13% | 16% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view CCL Products insights
59 extracted metrics + investor summaries across FY08–FY27.
Documents
Frequently Asked Questions about CCL Products
What does CCL Products (India) Ltd do?
Where is CCL Products (India) Ltd (CCL) listed?
Which sector does CCL Products (India) Ltd belong to?
What is the market capitalisation of CCL Products (India) Ltd?
What is the PE ratio of CCL Products (India) Ltd?
What is the 52-week high and low of CCL Products (India) Ltd?
Does CCL Products (India) Ltd pay dividends?
What is the Return on Equity (ROE) of CCL Products (India) Ltd?
Company Information
CCL Products (India) is engaged in the production, trading and distribution of Coffee. The Company has business operations mainly in India, Vietnam and Switzerland countries.(Source : 202003 Annual Report Page No:119)
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CCL.md for CCL Products (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.